PepGen (PEPG)
(Delayed Data from NSDQ)
$13.16 USD
-0.49 (-3.59%)
Updated May 17, 2024 04:00 PM ET
After-Market: $13.16 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Price, Consensus and EPS Surprise
PEPG 13.16 -0.49(-3.59%)
Will PEPG be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for PEPG based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PEPG
Best Momentum Stocks to Buy for April 25th
New Strong Buy Stocks for April 25th
PEPG: What are Zacks experts saying now?
Zacks Private Portfolio Services
Can PepGen, Inc. (PEPG) Climb 48.62% to Reach the Level Wall Street Analysts Expect?
PepGen, Inc. (PEPG) Upgraded to Buy: What Does It Mean for the Stock?
PepGen (PEPG) Down on Clinical Hold for DM1 Candidate
Other News for PEPG
PepGen Inc.: A Buy Rating Ahead of Pivotal Clinical Data Release and Strong Fiscal Health
PepGen reports Q1 results
PepGen Inc. (PEPG) Receives a Buy from Wedbush
Analysts Offer Insights on Healthcare Companies: OptimizeRx (OPRX), PepGen Inc. (PEPG) and RegenXBio (RGNX)
Buy Rating on PepGen Inc. Backed by PGN-EDO51’s Efficacy and Safety Profile